Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT02599714
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02569801
- Locations
- 🇺🇸
Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States
🇺🇸The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Fondazione Sandro Pitigliani
- Target Recruit Count
- 115
- Registration Number
- NCT02549430
- Locations
- 🇮🇹
Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy
🇮🇹Istituto Europeo Oncologia, Milano, Italy
🇮🇹Ospedale Antonio Perrino, Brindisi, Italy
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
- Conditions
- Interventions
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02540330
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸The Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 124
- Registration Number
- NCT02536742
- Locations
- 🇧🇪
CHU Liege, Liège, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇮🇹Azienda USL4 Prato, Prato, Italy
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Velindre NHS Trust
- Target Recruit Count
- 160
- Registration Number
- NCT02530411
- Locations
- 🇬🇧
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom
🇬🇧Royal United Hospital Bath, Bath, United Kingdom
"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 102
- Registration Number
- NCT02530424
- Locations
- 🇮🇹
Istituto Europeo di Oncologia, Milano, MI, Italy
🇮🇹Policlinico Sant'Orsola Malpighi, Bologna, BO, Italy
🇮🇹Azienda Ospedaliero Universitaria di Ferrara - Arcispedale S. Anna, Ferrara, FE, Italy
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 486
- Registration Number
- NCT02491983
- Locations
- 🇪🇸
MedSIR investigative site B, Zaragoza, Spain
🇬🇧MedSIR investigative site, Truro, United Kingdom
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT02476786
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT02447328
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.